AKT1 and cancer: Of the twenty-two compounds with a Cmap score of 90 or greater, six have been reported to have activity in other cancer cell lines against the PI3K/Akt/mTOR pathway, five as protein synthesis inhibitors, three as protein kinase inhibitors, and three of the compounds as cell cycle inhibitors.